利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

428 条记录 (耗时 0.017 秒)

    SUSTAINED DRUG DELIVERY IMPLANT
    1.
    发明公开
    SUSTAINED DRUG DELIVERY IMPLANT 审中-公开
    IMPLANTAT MIT LANGZEIT-WIRKSTOFFFREISETZUNG

    公开(公告)号：EP2956096A1

    公开(公告)日：2015-12-23

    申请号：EP14709018.7

    申请日：2014-02-14

    申请人： ALLERGAN, INC.

    发明人： SHIAH, Jane Guo ,  PUJARA, Chetan P.

    IPC分类号： A61F9/00 ,  A61K9/00

    CPC分类号： A61K9/0051 ,  A61F9/0017 ,  A61F2210/0004 ,  A61K31/498 ,  A61K47/32 ,  Y10S514/912 ,  Y10S514/913 ,  Y10S514/953 ,  Y10S514/954 ,  Y10S514/956

    摘要： Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.

    摘要翻译： 生物相容性眼内植入物可以包括溴莫尼定游离碱和与溴莫尼定游离碱相关的可生物降解的聚合物，以促进将溴莫尼定游离碱释放到眼睛中，聚合物基质持续不超过药物释放持续时间的两倍， 但超过药物释放持续时间。

    Deprenyl compounds for treatment of glaucoma
    7.
    发明公开
    Deprenyl compounds for treatment of glaucoma 失效
    Deprenyl Verbindungen zur Behandlung von Glaukom

    公开(公告)号：EP1614415A1

    公开(公告)日：2006-01-11

    申请号：EP05020890.9

    申请日：1996-02-12

    申请人： THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION

    发明人： Tatton, William G.

    IPC分类号： A61K31/135

    CPC分类号： A61K31/137 ,  A61K31/135 ,  Y10S514/913

    摘要： Methods and kits for treatment of glaucoma are disclosed. In general, the methods of the invention include administering a therapeutically effective amount of a deprenyl compound to a subject such that the subject is treated for glaucoma.

    摘要翻译： 公开了用于治疗青光眼的方法和试剂盒。 通常，本发明的方法包括向受试者施用治疗有效量的去肾上腺素化合物，使得受试者被治疗青光眼。

    (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES FOR THE TREATMENT OF NEURAL INJURY
    8.
    发明授权
    (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES FOR THE TREATMENT OF NEURAL INJURY 有权
    （2-咪唑啉-2-基氨基）喹喔啉用于治疗神经损伤

    公开(公告)号：EP1146877B1

    公开(公告)日：2005-11-30

    申请号：EP00906868.5

    申请日：2000-01-04

    申请人： ALLERGAN, INC.

    发明人： WHEELER, Larry, A. ,  WOLDEMUSSIE, Elizabeth ,  LAI, Ronald, K.

    IPC分类号： A61K31/495 ,  A61P27/06

    CPC分类号： A61K31/498 ,  A61K31/495 ,  Y10S514/912 ,  Y10S514/913

    摘要： The present invention provides a method of protecting the optic or retinal nerve cells of a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on said nerve cells an effective amount of a compound of formula (I) to inhibit or prevent nerve cell injury or death, wherein the 2-imidazolin 2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy, or pharmaceutically acceptable salts thereof and mixtures thereof. Such noxious action may result from glaucomatous optic neuropathy, age related macular degeneration or retinitis pigmentosa.